Thermo Fisher Scientific Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Thermo Fisher Scientific Inc. for the quarter ended June 28, 2008. The company operates in two primary segments: Analytical Technologies and Laboratory Products and Services. It develops, manufactures, and sells a broad range of products for life sciences, environmental, and healthcare industries globally.
Key Financial Metrics
| Metric (in millions) | Q2 2008 | Q2 2007 | YTD 6mo 2008 | YTD 6mo 2007 |
|---|---|---|---|---|
| Revenues | $2,709.6 | $2,385.9 | $5,263.6 | $4,724.1 |
| Operating Income | $330.2 | $243.0 | $620.6 | $435.4 |
| Net Income | $249.5 | $163.9 | $482.5 | $302.8 |
| Diluted EPS | $0.57 | $0.37 | $1.10 | $0.68 |
| Operating Margin | 12.2% | 10.2% | 11.8% | 9.2% |
| Cash from Operations (6mo) | $590.3 million (vs. $556.4 million in 2007) | |||
| Total Debt | ~$2.19 billion (93% due 2010+) | |||
| Cash & Equivalents | $1.007 billion (as of June 28, 2008) |
Material Changes vs. Prior Period
- Revenue Growth: Q2 2008 revenues increased 14% ($324 million) compared to Q2 2007. Growth was driven by a $183 million increase in organic demand, $51 million from acquisitions, and $90 million from favorable currency translation.
- Profitability: Operating income rose 36% to $330.2 million. Margins expanded due to price increases, merger integration savings, and lower restructuring costs.
- Restructuring Impact: The company recorded a net restructuring income of $5.4 million in Q2 2008, compared to costs of $8.3 million in Q2 2007. This improvement was primarily due to an $18.5 million gain from the curtailment of a U.S. defined benefit pension plan.
- Segment Performance:
- Analytical Technologies: Revenue up 14% to $1.16 billion; Operating margin improved to 21.1%.
- Laboratory Products and Services: Revenue up 14% to $1.66 billion; Operating margin held steady at 14.0%, offsetting material cost inflation (resins, steel, fuel) with productivity gains.
- Acquisitions: In the first six months of 2008, the company completed acquisitions with aggregate consideration of $32 million cash plus $8 million assumed debt.
Guidance, Outlook, and Risks
- Tax Rate: Management expects the full-year effective tax rate to be approximately 19% - 20%, higher than the 15.5% in Q2 2007 due to increased income in higher-tax jurisdictions.
- Capital Expenditures: Expected to approximate $230 - $250 million for the full year 2008.
- Customer Agreement: A revised agreement with a major healthcare market customer is expected to decrease sales volume by approximately $20 million for the remainder of 2008 and $60 million in 2009.
- Accounting Changes: Adoption of FSP APB No. 14-1 in 2009 is expected to increase annual interest expense by approximately $23 million, reducing EPS by roughly $0.03.
- Risks:
- Litigation: Ongoing patent infringement lawsuit filed by Applera Corporation/MDS Inc. regarding mass spectrometer systems; an unfavorable outcome could be material.
- Environmental: Potential remediation costs related to historical contamination at acquired facilities.
- Commodity Prices: Exposure to rising costs of fuel, petroleum-based resins, steel, and serum.
Investor Verification Checklist
- Pension Curtailment Gain: Verify the sustainability of the $18.5 million one-time gain from the pension plan curtailment that significantly boosted Q2 earnings.
- Customer Concentration: Assess the impact of the revised agreement with the major healthcare customer, which projects an $80 million annualized revenue decrease.
- Restructuring Reserves: Review the remaining accrued restructuring costs ($18.2 million total) and the timeline for payments (through 2013 for facility abandonments).
- Goodwill Valuation: Monitor the $8.72 billion goodwill balance for potential impairment risks given the high level of acquisitions.
- Future Interest Expense: Confirm the projected $23 million increase in interest expense due to the 2009 adoption of FSP APB No. 14-1.